Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L J Goldsmith

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
JPEN. Journal of Parenteral and Enteral Nutrition|January 1, 1997
Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitisS A McClave, L M Greene, H L Snider, et al.
Pediatric Research|July 1, 1997
The administration of complement component C9 enhances the survival of neonatal rats with Escherichia coli sepsisH A Lassiter, B M Walz, J L Wilson, et al.
Leukemia & Lymphoma|October 8, 1999
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant GroupD R Fleming, S N Wolff, J W Fay, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
JPEN. Journal of Parenteral and Enteral Nutrition|January 1, 1997
Comparison of the safety of early enteral vs parenteral nutrition in mild acute pancreatitisS A McClave, L M Greene, H L Snider, et al.
Pediatric Research|July 1, 1997
The administration of complement component C9 enhances the survival of neonatal rats with Escherichia coli sepsisH A Lassiter, B M Walz, J L Wilson, et al.
Leukemia & Lymphoma|October 8, 1999
Protracted results of dose-intensive therapy using cyclophosphamide, carmustine, and continuous infusion etoposide with autologous stem cell support in patients with relapse or refractory Hodgkin's disease: a phase II study from the North American Marrow Transplant GroupD R Fleming, S N Wolff, J W Fay, et al.
Pageof 6